FTC To Drop Antitrust Suit Over Lundbeck Heart Defect Drug

Law360, New York (January 23, 2012, 5:36 PM EST) -- The Federal Trade Commission has decided not to ask the U.S. Supreme Court to revive its suit accusing Lundbeck Inc. of illegally cornering the market on drugs used to treat heart defects in premature babies, the agency said Friday.

The decision will leave in place the Eighth Circuit's August ruling affirming the dismissal of the case — brought jointly with the state of Minnesota — after the court concluded that the FTC had failed to identify a relevant market. The panel ruled that the two drugs...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.